Seattle-based Atossa Genetics, the developer of a new diagnostic test for breast cancer, said today it has raised $6.6 million in a private financing. The company, led by former Nastech Pharmaceuticals CEO Steven Quay, said it plans to use the money to introduce its new product in the Northwest, hire a sales force, and develop a next-generation form of the technology. Atossa, which was profiled here a year ago, at one point sought to raise $15 million through an initial public offering.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
